New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
06:57 EDTBDSIBioDelivery Sciences risk/reward profile favorable, says William Blair
William Blair reiterates an Outperform rating on shares of BioDelivery Sciences ahead of the June 7 PDUFA date for Bunavail, the company's buprenorphine/naloxone sublingual film for the treatment of opioid addiction. The firm says the FDA has been focused on new therapies for opioid addiction given the current opioid-abuse crisis. It views the risk/reward for BioDelivery shares as favorable and has a $16 price target for the stock.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
09:02 EDTBDSIAcceptance of NDA for Belbuca triggers $10M milestone payment to BDSI
Subscribe for More Information
07:31 EDTBDSIEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
February 20, 2015
08:21 EDTBDSISummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use